Phys Vivas · general-medicine
Anaphylaxis — Viva Defence
Structured DCE viva for anaphylaxis: long-case defence of recurrent idiopathic anaphylaxis — trigger reconstruction, mast-cell screening, autoinjector training and safety-net building, with probing questions and first-person model answers.
On this page
Study tools
Target exams
Opening statement (SASPOP, delivered aloud)
“Ms Tran is a 29-year-old teacher with recurrent anaphylaxis — three episodes in 14 months, at least one severe and multi-dose, and two currently unexplained. Her main problems are: an unconfirmed trigger profile with probable idiopathic anaphylaxis; an unreliable safety net — she does not consistently carry her autoinjector; an unexamined cofactor and medication load; and the occupational and psychological consequences of unpredictable reactions in a woman responsible for a classroom. I would like to reconstruct every episode minutely, screen her for mast-cell disease, rebuild her safety net with device training and action plans for home and school, and refer her to an immunologist for definitive trigger work and consideration of prophylactic therapy.” [3] [4]
References6ShowHide
- [1]Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium J Allergy Clin Immunol, 2006.PMID 16461139
- [2]Schwartz LB Diagnostic value of tryptase in anaphylaxis and mastocytosis Immunol Allergy Clin North Am, 2006.PMID 16931288
- [3]Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal Int Arch Allergy Immunol, 2012.PMID 22041891
- [4]Campbell RL, Li JT, Nicklas RA, et al. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter Ann Allergy Asthma Immunol, 2014.PMID 25466802
- [5]Turner PJ, Jerschow E, Umasunthar T, et al. Fatal Anaphylaxis: Mortality Rate and Risk Factors J Allergy Clin Immunol Pract, 2017.PMID 28888247
- [6]Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings Cochrane Database Syst Rev, 2012.PMID 23076950